177 related articles for article (PubMed ID: 23093228)
21. Detection of Pleural Fluid Biochemistry Changes in Two Consecutive Thoracenteses for Differentiating Malignant from Benign Effusions.
Bielsa S; García-Zamalloa A; Monteagudo P; González-Sans D; Ascanio D; Esquerda A; Taboada-Gómez J; Porcel JM
Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):320-326. PubMed ID: 29496288
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor alpha in the diagnostic assessment of pleural effusion.
Odeh M; Sabo E; Srugo I; Oliven A
QJM; 2000 Dec; 93(12):819-24. PubMed ID: 11110589
[TBL] [Abstract][Full Text] [Related]
23. Different expression of FoxM1 in human benign and malignant pleural effusion.
Tang Z; Li H; Zhu H; Bai C
Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.
Li J; Li ZN; Bao QL; Ge LP; Li XQ; Chen P
Tumour Biol; 2012 Oct; 33(5):1803-10. PubMed ID: 22696161
[TBL] [Abstract][Full Text] [Related]
25. Pleural fluid carbohydrate antigen 72-4 and malignant pleural effusion: a diagnostic test accuracy study.
Cao XS; Yan L; Jiang TW; Huang JH; Chen H; Porcel JM; Zheng WQ; Hu ZD
Ther Adv Respir Dis; 2024; 18():17534666231222333. PubMed ID: 38189269
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
Kuralay F; Tokgöz Z; Cömlekci A
Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
[TBL] [Abstract][Full Text] [Related]
27. Pleural and serum markers for diagnosis of malignant pleural effusion.
Allama AM; Abou-Elela DH; Ibrahim IM
Asian Cardiovasc Thorac Ann; 2020 Nov; 28(9):560-565. PubMed ID: 32741198
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion.
Basso SMM; Del Conte A; Zuccon U; Sulfaro SC; Fanti G; Maffeis F; Ubiali P; Ermani M; Lumachi F
Anticancer Res; 2020 Oct; 40(10):5877-5881. PubMed ID: 32988918
[TBL] [Abstract][Full Text] [Related]
29. Glucose transporter 1 protein detected by enzyme-linked immunosorbent assay and immunocytochemistry: a useful diagnostic tool for malignant pleural effusions.
Liao ND; Chiang TA; Lee WY
Cancer Cytopathol; 2013 Dec; 121(12):695-702. PubMed ID: 23861325
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
[TBL] [Abstract][Full Text] [Related]
31. Predicting malignant and tuberculous pleural effusions through demographics and pleural fluid analysis of patients.
Valdés L; San-José E; Ferreiro L; Golpe A; González-Barcala FJ; Toubes ME; Rodríguez-Álvarez MX; Álvarez-Dobaño JM; Rodríguez-Núñez N; Rábade C; Gude F
Clin Respir J; 2015 Apr; 9(2):203-13. PubMed ID: 25849297
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of procalcitonin in pleural effusions.
Wang CY; Hsiao YC; Jerng JS; Ho CC; Lai CC; Yu CJ; Hsueh PR; Yang PC
Eur J Clin Microbiol Infect Dis; 2011 Mar; 30(3):313-8. PubMed ID: 20938702
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.
Ozsu S; Oztuna F; Mentese A; Abul Y; Ozlu T
Clin Respir J; 2016 Jan; 10(1):61-6. PubMed ID: 25043397
[TBL] [Abstract][Full Text] [Related]
34. Pentraxin-3: A novel biomarker for discriminating parapneumonic from other exudative effusions.
Ozsu S; Abul Y; Mentese A; Bektas H; Uzun A; Ozlu T; Porcel JM
Respirology; 2013 May; 18(4):657-62. PubMed ID: 23286371
[TBL] [Abstract][Full Text] [Related]
35. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
36. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
37. Pleural fluid cell-free DNA in parapneumonic pleural effusion.
Santotoribio JD; Cabrera-Alarcón JL; Batalha-Caetano P; Macher HC; Guerrero JM
Clin Biochem; 2015 Oct; 48(15):1003-5. PubMed ID: 26234638
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of CEA in pleural fluid for differential diagnosis of benign and malign pleural effusion.
Radjenovic-Petkovic T; Pejcic T; Nastasijević-Borovac D; Rancic M; Radojkovic D; Radojkovic M; Djordjevic I
Med Arh; 2009; 63(3):141-2. PubMed ID: 20088159
[TBL] [Abstract][Full Text] [Related]
39. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Lee YC; Knox BS; Garrett JE
Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions.
Porcel JM; Vives M; Gázquez I; Vicente de Vera MC; Pérez B; Rubio M
Int J Tuberc Lung Dis; 2000 Jan; 4(1):76-82. PubMed ID: 10654648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
